secwatch.observer — SEC 8-K summary
======================================

Issuer:     Absci Corp (ABSI)
CIK:        0001672688
Form:       8-K
Filed at:   2026-03-24T23:59:59+00:00
Accession:  0001672688-26-000066
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Absci reports Q4 net loss $29.6M, advances ABS-201 trial, appoints new CMO
--------------------------------------------------------------------------

- Dosed first three cohorts in SAD portion of Phase 1/2a HEADLINE trial for ABS-201; well-tolerated with favorable emerging safety.
- Net loss Q4 2025 $29.6M vs $29.0M prior year; full year net loss $115.2M vs $103.1M.
- Cash, equivalents, and marketable securities $144.3M as of Dec 31, 2025; sufficient to fund operations into first half 2028.
- Appointed Ransi Somaratne, M.D. (former Vertex SVP) as Chief Medical Officer to lead clinical strategy.
- Interim proof-of-concept data for ABS-201 expected H2 2026; Phase 2 endometriosis trial initiation planned Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672688/000167268826000066/0001672688-26-000066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672688/000167268826000066/absc-20260324.htm
  HTML page:      https://secwatch.observer/filing/0001672688-26-000066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer